The cash cow is dead:
. . . safety questions about the stents have triggered steep sales declines and job cuts for the makers, and are expected to shrink the U.S. market by one-third this year — a $1 billion drop just four years after the tiny gizmos were introduced.J&J is cutting nearly 5,000 jobs due in part to a stent decline after studies questioned the devices’ safety and effectiveness in preventing heart attacks and bypass surgery. Boston Scientific is preparing its own cuts after its stock hit a five-year low and its credit rating sank below junk-bond status.
(via PharmaGossip)
Related posts:
- Stents take a hit
- Drug-coated stents
- What does open heart surgery look and sound like?
- Should you stop taking Vytorin if you’re already on the drug?
- The Weis trial continues
- Medical waste
- Marketing stents to consumers
KevinMD.com on Facebook
 
Follow on Twitter  
Subscribe







Comments on this entry are closed.